Substantial Equivalence (SE) is a regulatory determination by the FDA that a new medical device has the same intended use and technological characteristics as a legally marketed predicate device, or that any different technological characteristics do not raise new questions of safety or effectiveness. This determination forms the legal basis for clearance via the 510(k) premarket notification pathway, confirming the new device is at least as safe and effective as the predicate.
Glossary
Substantial Equivalence (SE)
An FDA determination that a new medical device is as safe and effective as a legally marketed predicate device, typically demonstrated through a 510(k) premarket notification.
REGULATORY DETERMINATION
What is Substantial Equivalence (SE)?
The foundational comparative analysis that allows a new medical device to be legally marketed by demonstrating it is as safe and effective as an existing legally marketed predicate device.
Establishing SE does not require the new device to be identical to the predicate; rather, it requires a detailed comparative analysis of indications for use, design, materials, and performance testing. When technological differences exist, the submission must include validation data—such as bench testing or clinical performance studies—demonstrating that these deviations do not adversely impact the device's safety or effectiveness profile relative to the predicate.
SUBSTANTIAL EQUIVALENCE
Core Components of an SE Determination
A Substantial Equivalence (SE) determination is the analytical backbone of a 510(k) submission. It requires a structured, side-by-side comparison proving a new device is as safe and effective as a legally marketed predicate device. The following components form the critical evidence chain.
02
Intended Use & Indications for Use Comparison
The Intended Use Statement defines the general purpose (e.g., diagnostic image analysis), while Indications for Use specify the patient population, anatomical site, and clinical context.
- Equivalence Standard: The new device's indications must fall within the predicate's cleared indications. A broader indication requires a new submission type.
- Technological Differences: Differences in the mechanism of action are acceptable only if they do not raise new questions of safety or effectiveness.
- Labeling Parity: The proposed labeling must not introduce new disease claims absent from the predicate's cleared labeling.
03
Technological Characteristics Comparison
A granular, feature-by-feature comparison of the device's design, materials, and energy source. For Software as a Medical Device (SaMD), this focuses on the algorithm's architecture and input data flow.
- Tabular Format: FDA expects a detailed table listing similarities and differences with a justification for each difference.
- Algorithmic Comparison: For locked algorithms, compare the specific mathematical methods. For adaptive algorithms, reference the Predetermined Change Control Plan (PCCP).
- Performance Data: Bench testing is required to prove that any technological differences do not degrade diagnostic accuracy.
04
Performance Testing & Benchmarking
Non-clinical bench testing provides the quantitative evidence that technological differences do not impact safety. This is the core of the analytical validation.
- Precision Studies: Demonstrate repeatability (same operator, same sample) and reproducibility (different operators, different days).
- Limit of Detection (LoD): For diagnostic AI, this translates to the minimum lesion size or signal intensity the algorithm can reliably detect.
- Robustness Testing: Stress-testing the algorithm against edge cases, such as corrupted DICOM headers or images with motion artifacts, to prove resilience.
05
Risk Management & Mitigation
A rigorous comparison of the hazard profiles, guided by ISO 14971. The SE determination must prove that any new risks introduced by technological changes are adequately controlled.
- Hazard Analysis: Identify failure modes like false negatives caused by a new neural network architecture.
- Risk Control: Map each identified hazard to a specific mitigation, such as a confidence score threshold or a human-in-the-loop workflow.
- Cybersecurity Risk: For connected SaMD, a Cybersecurity Risk Assessment must demonstrate that the new device does not introduce network vulnerabilities absent in the predicate.
06
Human Factors & Labeling Evaluation
The user interface and labeling must not introduce use-related hazards that differ from the predicate. Human Factors Engineering (HFE) validation is critical for diagnostic AI.
- Use Error Analysis: Evaluate if a new visualization (e.g., a saliency map overlay) could mislead a clinician into over-diagnosis.
- Labeling Comprehension: Test that the intended user understands the algorithm's limitations, such as specific anatomical blind spots.
- Training Parity: If the predicate required no specific user training, the new device must demonstrate equivalent intuitive usability.
REGULATORY CLARITY
Frequently Asked Questions
Clear, technically precise answers to the most common questions about establishing Substantial Equivalence for Software as a Medical Device.
Substantial Equivalence (SE) is a regulatory determination by the FDA that a new medical device is as safe and effective as a legally marketed predicate device. It is the foundational principle of the 510(k) Premarket Notification pathway. To establish SE, a manufacturer must demonstrate that the new device has the same intended use as the predicate and that any technological differences do not raise new questions of safety or effectiveness. For Software as a Medical Device (SaMD), this often involves comparing algorithmic performance characteristics—such as sensitivity and specificity—against the predicate through rigorous analytical validation and clinical evaluation studies. The comparison is not required to show that the devices are identical, only that the new device's performance is at least equivalent to the predicate's established safety and effectiveness profile.
REGULATORY PATHWAY COMPARISON
Substantial Equivalence vs. Other FDA Pathways
A comparative analysis of the 510(k) Substantial Equivalence pathway against the De Novo and Premarket Approval (PMA) routes for medical device clearance.
| Feature | 510(k) Substantial Equivalence | De Novo Classification | Premarket Approval (PMA) |
|---|---|---|---|
Regulatory Basis | FD&C Act Section 510(k); 21 CFR 807 Subpart E | FD&C Act Section 513(f)(2); 21 CFR 860 Subpart D | FD&C Act Section 515; 21 CFR 814 |
Device Risk Class | Class II (moderate risk) | Class I or II (low to moderate risk) | Class III (high risk) |
Predicate Device Required | |||
Clinical Data Typically Required | ~10% of submissions | Often required for novel tech | |
Review Timeline (FDA Goal) | 90 days | 150 days | 180 days |
User Fee (FY2024 Standard) | $21,760 | $145,068 | $483,560 |
Primary Evidence Standard | Substantial equivalence to predicate | Reasonable assurance of safety and effectiveness | Valid scientific evidence of safety and effectiveness |
Post-Market Requirements | General controls + special controls | General controls + special controls | General controls + PMA-specific post-approval studies |
Enabling Efficiency, Speed & Accuracy
Intelligent Analysis, Decision & Execution
We build AI systems for teams that need search across company data, workflow automation across tools, or AI features inside products and internal software.
Talk to Us
Search across company data
Give teams answers from docs, tickets, runbooks, and product data with sources and permissions.
Useful when people spend too long searching or get different answers from different systems.
Enterprise searchRAGPermissions
Read more
Automate internal workflows
Use AI to route work, draft outputs, trigger actions, and keep approvals and logs in place.
Useful when repetitive work moves across multiple tools and teams.
AI agentsWorkflow automationGovernance
Read more
Add AI to products and internal tools
Build assistants, guided actions, or decision support into the software your team or customers already use.
Useful when AI needs to be part of the product, not a separate tool.
AI integrationDecision supportModel routing
Read more
About the author
Prasad Kumkar
CEO & MD, Inference Systems
Prasad Kumkar is the CEO & MD of Inference Systems and writes about AI systems architecture, LLM infrastructure, model serving, evaluation, and production deployment. Over 5+ years, he has worked across computer vision models, L5 autonomous vehicle systems, and LLM research, with a focus on taking complex AI ideas into real-world engineering systems.
His work and writing cover AI systems, large language models, AI agents, multimodal systems, autonomous systems, inference optimization, RAG, evaluation, and production AI engineering.
LinkedIn
Limited slotsGet a Free AI Consultation
Partnered with leading AI, data, and software stack.
How We Work
Custom AI workflows for your Business
One-fit-all AI don't work for modern businesses. At Inferensys, we aim to understand your business & custom requirements; which we use to define most efficient agentic workflows, the data, and the tools for your business.
01
Review the use case
We understand the task, the users, and where AI can actually help.
Read more02
Pick the right approach
We define what needs search, automation, or product integration.
Read more03
Build the first useful version
We implement the part that proves the value first.
Read more04
Improve from there
We add the checks and visibility needed to keep it useful.
Read moreThe first call is a practical review of your use case and the right next step.
Talk to Us